Delineating The Clinical And Molecular Heterogeneity Of Fatty Liver Disease To Inform Treatment
Funder
National Health and Medical Research Council
Funding Amount
$1,731,372.00
Summary
Fatty liver disease from excess weight affects 1 in 3 adult Australians. The disease has no treatments and many patients develop liver failure or liver cancer. Clinically, the disease is characterized by marked heterogeneity, a challenge for developing biomarkers and treatments. To move towards precision medicine, this project will undertake an inter-disciplinary program that embraces disease complexity and integrates environmental and genetic risk with the power of mathematical modelling.